REGN241227C860000
- 2.43
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt
Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control
Express News | Regeneron Pharmaceuticals Inc - Phase 3 Program to Begin in 2025
Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study